ArriVent BioPharma (AVBP) Expected to Announce Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect ArriVent BioPharma to post earnings of ($0.78) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.18. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Stock Performance

Shares of ArriVent BioPharma stock opened at $18.99 on Wednesday. The stock has a market capitalization of $645.96 million, a price-to-earnings ratio of -7.39 and a beta of 1.00. The company has a fifty day moving average of $24.70 and a 200-day moving average of $26.62. ArriVent BioPharma has a 52-week low of $14.35 and a 52-week high of $36.37.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AVBP. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price objective on shares of ArriVent BioPharma in a research note on Friday, March 7th. Guggenheim began coverage on ArriVent BioPharma in a research report on Monday, March 10th. They set a “buy” rating and a $45.00 price target on the stock. Finally, B. Riley initiated coverage on ArriVent BioPharma in a research report on Thursday, March 20th. They issued a “buy” rating and a $37.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $39.00.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.